These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15806436)

  • 1. [Indirect costs in idiopathic Parkinson's disease].
    Barth F; Baum B; Bremen D; Meuser T; Jost WH
    Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of illness in Parkinson's disease.
    Huse DM; Schulman K; Orsini L; Castelli-Haley J; Kennedy S; Lenhart G
    Mov Disord; 2005 Nov; 20(11):1449-54. PubMed ID: 16007641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
    Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
    Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early retirement and income loss in patients with early and advanced Parkinson's disease.
    Johnson S; Davis M; Kaltenboeck A; Birnbaum H; Grubb E; Tarrants M; Siderowf A
    Appl Health Econ Health Policy; 2011 Nov; 9(6):367-76. PubMed ID: 21919541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost and quality aspects in the treatment of Parkinson's disease].
    Müller T; Dodel R; Fritze J
    Z Arztl Fortbild Qualitatssich; 2006; 100(4):291-5. PubMed ID: 16878798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic impact of Parkinson's disease.
    Findley LJ
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S8-S12. PubMed ID: 17702630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.
    Noyes K; Liu H; Li Y; Holloway R; Dick AW
    Mov Disord; 2006 Mar; 21(3):362-72. PubMed ID: 16211621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany.
    Hamer HM; Spottke A; Aletsee C; Knake S; Reis J; Strzelczyk A; Oertel WH; Rosenow F; Dodel R
    Epilepsia; 2006 Dec; 47(12):2165-72. PubMed ID: 17201718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
    Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
    J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
    Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
    Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct medical costs associated with Parkinson's disease: a population-based study.
    Leibson CL; Long KH; Maraganore DM; Bower JH; Ransom JE; O'Brien PC; Rocca WA
    Mov Disord; 2006 Nov; 21(11):1864-71. PubMed ID: 16977632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.
    Hjelmgren J; Ghatnekar O; Reimer J; Grabowski M; Lindvall O; Persson U; Hagell P
    Parkinsonism Relat Disord; 2006 Oct; 12(7):443-52. PubMed ID: 16798054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current and projected economic burden of Parkinson's disease in the United States.
    Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A
    Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health-economic burden of Parkinson's disease in Portugal: a cohort study].
    Reese JP; Winter Y; Rosa MM; Rodrigues E Silva AM; von Campenhausen S; Freire R; Mateus C; Balzer-Geldsetzer M; Botzel K; Oertel WH; Dodel R; Sampaio C
    Rev Neurol; 2011 Mar; 52(5):264-74. PubMed ID: 21341221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].
    Dengler I; Leukel N; Meuser T; Jost WH
    Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug costs for patients with Parkinson's disease in two different European countries.
    Vossius C; Gjerstad M; Baas H; Larsen JP
    Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.